Methylprednisolone (Medrol®, Solu-Medrol®)
Glucocorticoid. 6-methyl derivative of prednisolone. Anti-inflammatory.
Molecular weight: 374.48
Methylprednisolone crosses the human placenta .
suggest a possible increased risk of oral cleft when corticosteroids are used
during the first trimester of pregnancy in humans [2, 3].
Methylprednisolone has been used to treat hyperemesis gravidarum during early
pregnancy. Safari et al. treated 20 women for hyperemesis gravidarum beginning at 7 to 12
16 mg orally 3 times a day for 3 days, followed by a tapering regimen
(halving of dose every 3 days) to none during the course of 2 weeks. Birth
information was available for 12 patients. One patient delivered
an infant with Smith-Lemli-Opitz syndrome at 35 weeks'. No birth defects were
reported in the other 11 infants 
Yost NP et al., compared the outcomes of 56 pregnant women treated for hyperemesis gravidarum
with methylprednisolone to a control group of 54 women who received a placebo.
The gestational ages at randomization were between 8 to 14 weeks' .
Women in the corticosteroid group received with methylprednisolone 125 mg IV followed by an oral prednisone taper
(40 mg for 1 day, 20 mg for 3 days, 10 mg for 3 days, 5 mg for 7 days). During
the trial there was one stillborn fetus, at 29 weeks, in a woman who
received corticosteroids. One woman in the placebo group delivered a premature
infant with microcephaly at 27 weeks. No other birth defects were reported
The National Asthma Education Program Working Group on Asthma and Pregnancy
does not consider the indications for the use of
methylprednisolone in the control of severe asthma exacerbations to be altered by pregnancy
BREAST FEEDING: We were unable to locate studies specifically addressing the
use of methylprednisolone during breastfeeding. Based on studies of prednisolone transfer
to breast milk infant exposure to corticosteroid would be expected to be minimal [7,8].